Workflow
络活喜
icon
Search documents
铂睿时 Iberis RDN:顺应指南,引领高血压治疗新变革
思宇MedTech· 2025-08-18 08:20
Core Viewpoint - The release of the 2025 ACC/AHA hypertension clinical guidelines indicates a new direction for hypertension prevention and treatment, highlighting the need for innovative solutions like renal denervation (RDN) to address the global challenge of uncontrolled hypertension [1]. Group 1: Differences Between US and China Guidelines - The US guidelines emphasize early intervention and precise stratification, setting the hypertension threshold at 130/80 mmHg to promote proactive management [2]. - The control targets in the US guidelines recommend a universal goal of <130/80 mmHg, with further specifications for high cardiovascular risk patients to lower systolic pressure to <130 mmHg, ideally <120 mmHg [3]. - In contrast, the Chinese guidelines set the hypertension threshold at 140/90 mmHg, aligning with local epidemiological characteristics and focusing on practical clinical management [4][5]. Group 2: RDN Clinical Application Under Guidelines - The 2025 US hypertension guidelines outline a comprehensive process for RDN application, emphasizing "precise selection, collaborative decision-making, and long-term management" [6]. - RDN is primarily indicated for patients with resistant hypertension, specifically those requiring three or more antihypertensive medications without achieving control [7]. - A multidisciplinary team (MDT) is essential for evaluating patients for RDN, ensuring thorough screening for secondary hypertension and contraindications [9]. Group 3: RDN as a New Treatment Option - RDN is recognized as a valuable adjunct treatment for resistant hypertension, with a recommendation level of 2b, B-R in the 2025 guidelines, indicating its use under specific conditions [11]. - The Iberis RDN system demonstrates significant efficacy, with a study showing a 13 mmHg reduction in 24-hour ambulatory systolic blood pressure and a 21 mmHg reduction in office systolic blood pressure at six months post-treatment [13]. - RDN offers a continuous blood pressure-lowering effect, providing a promising solution for patients with difficult-to-treat hypertension [13][14].
原料药巨头、医药平台多策略布局市场
Guang Zhou Ri Bao· 2025-05-02 04:27
Group 1 - The core viewpoint is that Noratech Biotech has benefited from the growth in the weight loss drug market, with over 60% of its revenue coming from overseas in 2024 [1][2] - The company reported a revenue of 1.625 billion yuan in 2024, representing a year-on-year growth of 57.21%, and a net profit of 404 million yuan, up 148.19% year-on-year [2] - Noratech Biotech is focusing on expanding its production capacity and entering emerging markets such as Southeast Asia, South America, and Russia to meet the high demand for peptide raw materials [2] Group 2 - The company has implemented several strategies to address market challenges, including global expansion, flexible trade arrangements, customer pricing strategies, and continuous cost reduction through technological innovation [2] - The demand for peptide raw materials is significant, and the company has established strategic partnerships with global clients, expanding beyond traditional markets to include Latin America and the Middle East [2] - The platform for imported chronic disease medications is experiencing strong supply and demand, with stable supply of original imported drugs and measures in place to ensure price stability [3]